Unnamed: 0,title,date,stock,sentiment
327833.0,34 Stocks Moving in Wednesday's Pre-Market Session,2020-06-10 07:17:00-04:00,CYCC,neutral
327834.0,"Cyclacel Pharma Shares Spike To Session High, Up 4.6%; Hearing Research Firm Brookline Initiated Coverage On Stock With Buy Rating, $22 Price Target",2020-05-19 11:28:00-04:00,CYCC,positive
327835.0,Cyclacel Pharmaceuticals Q1 EPS $(2.770) Beats $(2.900) Estimate,2020-05-12 16:06:00-04:00,CYCC,neutral
327836.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,CYCC,negative
327837.0,"Cyclacel Pharmaceuticals On April 29, Was Notified By Nasdaq That Co Has Evidenced Full Compliance With All Criteria For Continued Lisiting",2020-05-04 16:48:00-04:00,CYCC,neutral
327838.0,Pesistance Pays: How I've Kept April's Green Streak Alive,2020-04-24 14:45:00-04:00,CYCC,positive
327839.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,CYCC,negative
327840.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,CYCC,negative
327841.0,52 Biggest Movers From Yesterday,2020-04-22 04:36:00-04:00,CYCC,neutral
327842.0,Mid-Afternoon Market Update: Dow Slides 500 Points; Vaxart Shares Spike Higher,2020-04-21 14:34:00-04:00,CYCC,positive
327843.0,44 Stocks Moving In Tuesday's Mid-Day Session,2020-04-21 12:31:00-04:00,CYCC,neutral
327844.0,Mid-Day Market Update: TriState Capital Jumps Following Q1 Results; Cyclacel Pharmaceuticals Shares Plunge,2020-04-21 12:17:00-04:00,CYCC,positive
327845.0,Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Estimates,2020-04-21 10:23:00-04:00,CYCC,positive
327846.0,Cyclacel Pharmaceuticals shares are trading lower after the company priced its 4 million share offering at $5 per share.,2020-04-21 09:26:00-04:00,CYCC,positive
327847.0,"Cyclacel Pharma Prices 4M Share, Warrant Offering At $5/Share",2020-04-21 08:28:00-04:00,CYCC,positive
327848.0,30 Stocks Moving in Tuesday's Pre-Market Session,2020-04-21 07:18:00-04:00,CYCC,neutral
327849.0,78 Biggest Movers From Yesterday,2020-04-21 04:32:00-04:00,CYCC,neutral
327850.0,Mid-Afternoon Market Update: Dow Falls Over 400 Points; NovaBay Pharmaceuticals Shares Jump,2020-04-20 14:31:00-04:00,CYCC,positive
327851.0,54 Stocks Moving In Monday's Mid-Day Session,2020-04-20 12:43:00-04:00,CYCC,neutral
327852.0,Mid-Day Market Update: Crude Oil Plunges 45%; Cyclacel Pharmaceuticals Shares Jump,2020-04-20 12:04:00-04:00,CYCC,negative
327853.0,Nano-Cap Cyclacel Rockets Higher On Launch Of Study For Coronavirus Inflammation,2020-04-20 11:33:00-04:00,CYCC,neutral
327854.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,CYCC,neutral
327855.0,Mid-Morning Market Update: Markets Open Lower ; Halliburton Earnings Top Views,2020-04-20 10:16:00-04:00,CYCC,negative
327856.0,Cyclacel Pharmaceuticals shares are trading higher after the company announced a collaboration agreement with the University of Edinburgh to study its CDK Inhibitors to reduce runaway inflammation in coronavirus disease.,2020-04-20 07:33:00-04:00,CYCC,positive
327857.0,35 Stocks Moving in Monday's Pre-Market Session,2020-04-20 07:20:00-04:00,CYCC,neutral
327858.0,Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease,2020-04-20 07:01:00-04:00,CYCC,negative
327859.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,CYCC,neutral
327860.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-15 10:48:00-04:00,CYCC,neutral
327861.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,CYCC,neutral
327862.0,"Cyclacel Pharma Reports 1-For-20 Reverse Stock Split, Effective Apr. 14, 2020",2020-04-14 12:32:00-04:00,CYCC,positive
327863.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,CYCC,neutral
327864.0,Cyclacel Pharmaceuticals Q4 EPS $(0.17) Misses $(0.13) Estimate,2020-02-26 16:29:00-05:00,CYCC,negative
327865.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,CYCC,negative
327866.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,CYCC,neutral
327867.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,CYCC,neutral
327868.0,85 Biggest Movers From Yesterday,2020-01-14 04:52:00-05:00,CYCC,neutral
327869.0,41 Stocks Moving In Monday's Mid-Day Session,2020-01-13 12:21:00-05:00,CYCC,neutral
327870.0,25 Stocks Moving in Monday's Pre-Market Session,2020-01-13 07:30:00-05:00,CYCC,neutral
327871.0,Cyclacel Pharmaceuticals shares are trading lower after the company announced it received a notice of delisting or failure to satisfy a continued listing rule or standard.,2020-01-10 16:42:00-05:00,CYCC,negative
327872.0,Cyclacel Pharmaceuticals Announces It Received Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,2020-01-10 16:11:00-05:00,CYCC,negative
327873.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,CYCC,neutral
327874.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,CYCC,neutral
327875.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,CYCC,positive
327876.0,30 Stocks Moving in Thursday's Pre-Market Session,2019-11-14 07:29:00-05:00,CYCC,neutral
327877.0,Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results.,2019-11-13 16:37:00-05:00,CYCC,positive
327878.0,Cyclacel Pharmaceuticals Q3 EPS $(0.11) Beats $(0.16) Estimate,2019-11-13 16:20:00-05:00,CYCC,neutral
327879.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,CYCC,neutral
327880.0,Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors,2019-09-09 07:05:00-04:00,CYCC,positive
327881.0,Stocks That Hit 52-Week Lows On Thursday,2019-08-15 11:29:00-04:00,CYCC,negative
327882.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-14 12:46:00-04:00,CYCC,negative
327883.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,CYCC,negative
327884.0,Cyclacel Pharmaceuticals Q2 EPS $(0.11) Up From $(0.16) YoY,2019-08-13 16:20:00-04:00,CYCC,neutral
327885.0,Stocks That Hit 52-Week Lows On Tuesday,2019-08-13 11:08:00-04:00,CYCC,negative
327886.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,CYCC,neutral
327887.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,CYCC,positive
327888.0,Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients,2019-07-22 07:23:00-04:00,CYCC,positive
327889.0,50 Biggest Movers From Friday,2019-05-28 05:01:00-04:00,CYCC,neutral
327890.0,30 Stocks Moving In Friday's Mid-Day Session,2019-05-24 13:00:00-04:00,CYCC,neutral
327891.0,A Look At Benzinga Pro's Most-Searched Tickers For May 24,2019-05-24 12:50:00-04:00,CYCC,neutral
327892.0,Mid-Day Market Update: Hibbett Sports Jumps On Upbeat Earnings; Urban Tea Shares Plunge,2019-05-24 12:13:00-04:00,CYCC,positive
327893.0,Mid-Morning Market Update: Markets Open Higher; Foot Locker Misses Q1 Estimates,2019-05-24 10:12:00-04:00,CYCC,negative
327894.0,"Hearing Roth Capital Assumes Cyclacel Pharmaceuticals, Inc. - Common Stock at Buy, Announces Price Target $8",2019-05-24 09:48:00-04:00,CYCC,neutral
327895.0,Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.,2019-05-24 09:31:00-04:00,CYCC,positive
327896.0,Cyclacel Pharmaceuticals Q1 EPS $(0.12) Beats $(0.2) Estimate,2019-05-14 16:30:00-04:00,CYCC,neutral
327897.0,Cyclacel Pharma Give an Updated From Phase 1 Data,2019-04-01 07:05:00-04:00,CYCC,neutral
327898.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,CYCC,neutral
327899.0,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",2019-03-28 07:54:00-04:00,CYCC,neutral
327900.0,"Cyclacel Pharmaceuticals FY18 EPS $(0.62) vs $(1.95) In FY17, Collaboration, R&D Sales $150K",2019-03-27 16:18:00-04:00,CYCC,neutral
327901.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,CYCC,positive
327902.0,Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action,2019-03-26 12:46:00-04:00,CYCC,negative
327903.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Mar. 26, 2019",2019-03-26 08:19:00-04:00,CYCC,positive
327904.0,41 Stocks Moving In Monday's Mid-Day Session,2019-03-25 12:51:00-04:00,CYCC,neutral
327905.0,Cyclacel Pharma shares are trading higher after the company announced an independent investigation was published on the company's treatment.,2019-03-25 07:45:00-04:00,CYCC,positive
327906.0,Cyclacel Pharma Says a Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor,2019-03-25 07:14:00-04:00,CYCC,negative
327907.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,CYCC,neutral
327908.0,"Cyclacel Pharmaceuticals Says Approved Renewal Of Employment Agreements Of CEO Spiro Rombotis, CFO Paul Mcbarron",2019-01-07 06:29:00-05:00,CYCC,positive
327909.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,CYCC,neutral
327910.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,CYCC,negative
327911.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,CYCC,positive
327912.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,CYCC,positive
327913.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,CYCC,negative
327914.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,CYCC,positive
327915.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,CYCC,negative
327916.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,CYCC,neutral
327917.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,CYCC,negative
327918.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,CYCC,negative
327919.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,CYCC,negative
327920.0,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",2018-11-16 08:08:00-05:00,CYCC,positive
327921.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,CYCC,negative
327922.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,CYCC,negative
327923.0,Cyclacel Pharmaceuticals Q3 EPS $(0.18) Misses $(0.17) Estimate,2018-11-12 16:15:00-05:00,CYCC,negative
327924.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,CYCC,neutral
327925.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,CYCC,positive
327926.0,UPDATE: Cyclacel Spokesperson Iterated Co. Itself Will Not Be Presenting Data For Cystic Fibrosis Treatment,2018-10-18 17:53:00-04:00,CYCC,neutral
327927.0,"Cyclacel Spokesperson, When Asked About Earlier Spike In Stock, Circulation Of Trader Chatter Cystic Fibrosis Data Would Be Delivered Thurs., Noted Co.'s Licensee ManRos Therapeutics Will Be At 2018 North American Cystic Fibrosis Conference Oct. 18-20",2018-10-18 17:52:00-04:00,CYCC,neutral
327928.0,"Cyclacel Shares Spike Higher, Up 14% For Session; Data On Cystic Fibrosis Treatment Expected Out Thurs.",2018-10-18 14:01:00-04:00,CYCC,positive
327929.0,Cyclacel Pharma 8-K Shows $5M At-The-Market Offering,2018-10-04 16:36:00-04:00,CYCC,neutral
327930.0,Cyclacel Pharma Reports Strategic Alliance With MD Anderson Cancer Center For Study Of Novel Co. Medicines In Hematological Malignancies,2018-10-04 07:04:00-04:00,CYCC,negative
327931.0,"Cyclacel Pharmaceuticals Starts Phase 1b/2 Clinical Trial Of Sapacitabine With Olaparib, Study Will Enroll ~64 Patients",2018-09-10 07:02:00-04:00,CYCC,neutral
327932.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,CYCC,neutral
327933.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2018",2018-09-05 09:10:00-04:00,CYCC,positive
327934.0,"Roth Capital Initiates Coverage On Cyclacel Pharmaceuticals with Buy Rating, Announces $8 Price Target",2018-09-05 08:21:00-04:00,CYCC,neutral
327935.0,Cyclacel Pharmaceuticals Q2 EPS $(0.50) Misses $(0.12) Estimate,2018-08-09 16:47:00-04:00,CYCC,negative
327936.0,"Cyclacel Pharmaceuticals Q1 EPS $(0.12) Up From $(0.38) YoY, No Sales",2018-05-14 16:14:00-04:00,CYCC,negative
327937.0,Cyclacel Pharma Reports CYC065 CDK Inhibitor Showed Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia,2018-04-17 09:02:00-04:00,CYCC,negative
327938.0,Cyclacel Reports Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting,2018-04-16 07:06:00-04:00,CYCC,negative
327939.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,CYCC,neutral
327940.0,"Cyclacel Pharma Reports FY17 EPS $(1.95) vs $(3.50) In Prior Year, No Sales vs $843K YoY",2018-03-28 16:24:00-04:00,CYCC,negative
327941.0,Cyclacel Pharma FY17 EPS $(1.95) vs $(3.50) In FY16,2018-03-28 16:09:00-04:00,CYCC,neutral
327942.0,Cyclacel Pharma Reports Phase 1 Clinical Data With CYC065 CDK Inhibitor Selected For Oral Presentation At AACR,2018-03-15 07:15:00-04:00,CYCC,negative
327943.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-02-21 08:02:00-05:00,CYCC,neutral
327944.0,Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations,2018-02-21 07:14:00-05:00,CYCC,positive
327945.0,"Cyclacel Pharma Shares Up ~$0.06 Over Last Min. As Traders Circulate USPTO Abstract Related To Dosage Regimen For Sapacitabine, Seliciclib",2018-01-23 10:30:00-05:00,CYCC,positive
327946.0,Cyclacel Announces 2018 Objectives,2018-01-09 07:06:00-05:00,CYCC,neutral
327947.0,"Cyclacel Reports Results From Phase 3 Seamless Study At ASH: 'Although the study did not reach its primary endpoint of superiority in survival, we are encouraged by the higher complete remission rate'",2017-12-12 07:10:00-05:00,CYCC,positive
327948.0,"Cyclacel Pharma Reports Q3 EPS $(0.86) vs $(0.91) In Same Qtr. Last Year, Sales $205K",2017-11-09 16:08:00-05:00,CYCC,neutral
327949.0,Cyclacel Pharma Reports Full Results From Phase 2 Seamless Trial Have Been Selected For Oral Presentation At ASH,2017-11-01 09:04:00-04:00,CYCC,neutral
327950.0,"The Week Ahead: Earnings, Earnings, And More Earnings",2017-10-16 10:49:00-04:00,CYCC,neutral
327951.0,Cyclacel Pharma Shares Spike Higher Over Last Few Mins.; Upside Intensified In Stock As Shares Breached $1.95 Technical Level; Stock Up 10% For Session,2017-10-13 11:03:00-04:00,CYCC,positive
327952.0,"Seeing Profit Taking In Cyclacel Pharma Shares, Down 14% Fri. Following 21% Rally On Thurs. Amid No News",2017-09-22 13:13:00-04:00,CYCC,positive
327953.0,12 Biggest Mid-Day Losers For Friday,2017-09-22 12:34:00-04:00,CYCC,negative
327954.0,"Cyclaccel Shares Spike ~18% Higher Over Last Few Mins, Not Seeing Any News",2017-09-12 15:26:00-04:00,CYCC,positive
327955.0,"Cyclacel Pharmaceuticals Reports Q2 EPS $(0.50) vs $(1.01) In Same Qtr. Last Year, Sales $222K",2017-08-09 17:26:00-04:00,CYCC,neutral
327956.0,Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide,2017-07-19 14:30:00-04:00,CYCC,positive
327957.0,15 Biggest Mid-Day Losers For Wednesday,2017-07-19 12:48:00-04:00,CYCC,negative
327958.0,Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet,2017-07-19 12:04:00-04:00,CYCC,negative
327959.0,Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates,2017-07-19 10:08:00-04:00,CYCC,neutral
327960.0,Cyclacel Pharma Reports Pricing Of Offering For $13.2M In Gross Proceeds,2017-07-19 08:31:00-04:00,CYCC,negative
327961.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-07-19 08:09:00-04:00,CYCC,neutral
327962.0,Cyclacel Pharmaceuticals Filing Shows Registration for Up to $5.06M Offering; Shares Down 29% in Premarket @$2.10,2017-07-19 06:17:00-04:00,CYCC,positive
327963.0,15 Biggest Mid-Day Gainers For Friday,2017-05-12 12:26:00-04:00,CYCC,neutral
327964.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-12 08:03:00-04:00,CYCC,neutral
327965.0,"Cyclacel Pharmaceuticals Reports Q1 EPS $(0.38) vs $(1.04) In Same Qtr. Last Year, Sales $139K",2017-05-11 16:38:00-04:00,CYCC,neutral
327966.0,14 Biggest Mid-Day Gainers For Monday,2017-04-10 14:06:00-04:00,CYCC,neutral
327967.0,Cyclacel Pop on Volume,2017-04-06 13:38:00-04:00,CYCC,neutral
327968.0,12 Biggest Mid-Day Losers For Wednesday,2017-04-05 13:06:00-04:00,CYCC,negative
327969.0,Adam Feuerstein Sees Major Price Manipulation In Small-Cap Pharma Stocks,2017-04-05 09:53:00-04:00,CYCC,negative
327970.0,"Feuerstein Showing Concern with Investors/Traders Getting Involved in Pharma Names: 'Know What You're Buying,' Sees Co. Mgmts as Taking Advantage of Investors Left Holding the Bag",2017-04-05 08:56:00-04:00,CYCC,positive
327971.0,"Feuerstein Believes 'Cyclacel is the Latest in a List of Stocks That Have Done This,' Says They Have Done Nothing, 'Certainly Not Developing Drugs' Are Good at Raising Money",2017-04-05 08:53:00-04:00,CYCC,positive
327972.0,"TheStreet's Adam Feuerstein on Benzinga's PreMarket Prep, Now Talking Cyclacel",2017-04-05 08:52:00-04:00,CYCC,neutral
327973.0,Noted Biotech Reporter Adam Feuerstein Will Be on Benzinga's PreMarket Prep Show in Just 2 Minutes at 8:50 a.m. EDT; We'll Be Talking Cyclacel premarket.benzinga.com,2017-04-05 08:48:00-04:00,CYCC,neutral
327974.0,"TheStreet's Adam Feuerstein Will Be on Benzinga's PreMarket Prep Wednesday, Apr. 5 at 8:50 a.m. EDT to Discuss Cyclacel, a Stock Which He Earlier Called 'A Zero'",2017-04-04 15:12:00-04:00,CYCC,neutral
327975.0,Adam Feuerstein Tweets: $CYCC Here's a story of mine from Jan. 10 about seliciclib. Spiros needed $. The drug still hasn't gone anywhere. thestreet.com/story/10658608…,2017-04-04 15:06:00-04:00,CYCC,neutral
327976.0,"Adam Feuerstein Tweets: $CYCC let pass golden oppty to burnish its stellar reputation w/ today's PR. Should have dropped ""Breakthrough"" ""Positive"" in the headline.",2017-04-04 13:16:00-04:00,CYCC,neutral
327977.0,"Cyclacel Issues Release Highlighting Presentation of Target Indications, Synergistic Drug Combos for CYC140, Says 'We believe these findings further validate the potential utility of CYC140 and its selection as a clinical candidate'",2017-04-04 13:01:00-04:00,CYCC,positive
327978.0,18 Biggest Mid-Day Gainers For Tuesday,2017-04-04 12:38:00-04:00,CYCC,neutral
327979.0,"Adam Feuerstein Unloads On Cyclacel Pharmaceuticals, Will Break Down Its Manipulation On PreMarket Prep",2017-04-04 12:24:00-04:00,CYCC,negative
327980.0,"Adam Feuerstein Tweets: $CYCC is a zero. You're trading worthless pieces of paper. And when the inevitable Rodman-led financing happens, you'll be a bag holder.",2017-04-04 11:26:00-04:00,CYCC,negative
327981.0,"Adam Feuerstein Tweets: The blatant manipulation of down-and-out, micro-cap biotech stocks is out of control. Regulators should step in. $CYCC",2017-04-04 11:19:00-04:00,CYCC,negative
327982.0,"Cyclacel Pharma Shares Resume, Continue Slightly Higher, Now Up 44%",2017-04-04 10:29:00-04:00,CYCC,positive
327983.0,Cyclacel Pharma Shares Will Resume at 10:29:13 a.m. EDT; BZ NOTE: Shares Up ~160% Over Last 2 Trading Sessions,2017-04-04 10:27:00-04:00,CYCC,positive
327984.0,"Cyclacel Pharma Shares Halted on Circuit Breaker, Now Up 40%",2017-04-04 10:25:00-04:00,CYCC,positive
327985.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-04 08:16:00-04:00,CYCC,neutral
327986.0,Cyclacel +40% Premarket @ $8.01,2017-04-04 07:46:00-04:00,CYCC,neutral
327987.0,Cyclacel +40% After-Hours @ $7.89,2017-04-03 17:16:00-04:00,CYCC,neutral
327988.0,Mid-Afternoon Market Update: NovoCure Surges After Two-Year Survival Rate Increases For GBM Patients; Diffusion Pharma Shares Slide,2017-04-03 14:44:00-04:00,CYCC,positive
327989.0,15 Biggest Mid-Day Gainers For Monday,2017-04-03 12:40:00-04:00,CYCC,neutral
327990.0,Mid-Day Market Update: Dow Drops Over 100 Points; DryShips Shares Plummet,2017-04-03 12:17:00-04:00,CYCC,positive
327991.0,Mid-Morning Market Update: Markets Edge Lower; Tesla Sets Deliveries Record In Q1,2017-04-03 10:14:00-04:00,CYCC,negative
327992.0,Cyclacel's Announces Presentation Demonstrating Therapeutic Potential of CYC065 in Lung Cancer at AACR 2017,2017-04-02 19:58:00-04:00,CYCC,negative
327993.0,"Cyclacel Pharmaceuticals Reports Q4 EPS $(1.18) vs. $(0.73) Est., Sales $424K vs. $210K Est.",2017-03-28 16:08:00-04:00,CYCC,neutral
327994.0,"Earnings Scheduled For March 28, 2017",2017-03-28 04:54:00-04:00,CYCC,neutral
327995.0,Cyclacell Pharma Spikes to High of $5.24 on Volume,2017-03-08 12:48:00-05:00,CYCC,neutral
327996.0,Mid-Afternoon Market Update: Dow Gains Over 50 Points; L Brands Shares Drop On Weak Forecast,2017-02-23 15:03:00-05:00,CYCC,negative
327997.0,Mid-Day Market Update: AXT Rises After Strong Q4 Results; Cyclacel Pharma Shares Tumble,2017-02-23 12:21:00-05:00,CYCC,positive
327998.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-02-23 08:29:00-05:00,CYCC,neutral
327999.0,UPDATE: Cyclacel CEO Says Co. Will Reevaluate Continued Investment In sapacitabine For Hematological Malignancies,2017-02-23 06:59:00-05:00,CYCC,neutral
328000.0,Cyclacel Announces Phase 3 SEAMLESS Study Did Not Meet Primary Endpoint,2017-02-23 06:58:00-05:00,CYCC,neutral
328001.0,"Cyclacel Pharma Shares Resume Trade, Now Up 12%",2016-11-21 09:59:00-05:00,CYCC,positive
328002.0,Cyclacel Pharmaceuticals Halted On Circuit Breaker,2016-11-21 09:54:00-05:00,CYCC,neutral
328003.0,"Cyclacel Pharmaceuticals Reports Q3 EPS $(0.86), Revenues $715K",2016-11-14 16:55:00-05:00,CYCC,neutral
328004.0,Technical Alert: Cyclacel Pharmaceuticals Comes Back To Earth,2016-08-22 13:33:00-04:00,CYCC,positive
328005.0,10 Biggest Mid-Day Gainers For Monday,2016-08-22 13:24:00-04:00,CYCC,neutral
328007.0,Cyclacel Pharmaceuticals Spikes to High of $9.22 on Volume,2016-08-22 10:28:00-04:00,CYCC,neutral
328008.0,Cyclacel Pharmaceuticals Reports Q2 EPS $(1.01) vs. Prior Year Quarter $(1.19),2016-08-10 16:08:00-04:00,CYCC,neutral
328009.0,9 Biggest Mid-Day Gainers For Monday,2016-06-06 12:17:00-04:00,CYCC,neutral
328010.0,"Cyclacel Pharma Shares Resume Following Second Circuit Breaker, Stock Continues Higher, Now Up 55.5%",2016-06-06 10:21:00-04:00,CYCC,positive
328011.0,"Cyclacel Pharma Shares Resume Trade, Up 44.5%, Halted on Second Circuit Breaker",2016-06-06 10:16:00-04:00,CYCC,positive
328012.0,"Shares of Cyclacel Pharma Halted on Circuit Breaker, Now Up 29.3%",2016-06-06 10:11:00-04:00,CYCC,positive
328013.0,"Cyclacel Offers Updated Data from DNA Damage Response Program on Seliciclib, Sapacitabine Combo in Patients with Solid Tumors: Showed 35.6% Disease Control Rate, Durable Responses",2016-06-06 10:02:00-04:00,CYCC,negative
328014.0,Cyclacel Reports 1-For-12 Reverse Stock Split,2016-05-27 17:01:00-04:00,CYCC,neutral
328015.0,"Cyclacel Pharmaceuticals Reports Q1 EPS $(0.09) vs. Prior Year Quarter $(0.19), Rev. $139K vs. Prior Year Quarter $512K",2016-05-11 16:07:00-04:00,CYCC,neutral
328016.0,Cyclacel Announces Will Remain Listed on Nasdaq,2016-04-11 07:04:00-04:00,CYCC,neutral
328017.0,"Cyclacel Pharma Reports Q4 EPS $(0.10) Vs Est $(0.08), Sales $400K Vs Est $510K",2016-03-24 16:07:00-04:00,CYCC,neutral
328018.0,"Earnings Scheduled For March 24, 2016",2016-03-24 04:06:00-04:00,CYCC,neutral
328019.0,Morning Market Losers,2015-11-30 09:51:00-05:00,CYCC,negative
328020.0,Benzinga's Top #PreMarket Losers,2015-11-30 08:25:00-05:00,CYCC,negative
328021.0,"Cyclacel -22% Premarket; Martin Shkreli in YouTube Live Stream on Sunday, Said Stock is Worthless",2015-11-30 07:06:00-05:00,CYCC,negative
328022.0,"UPDATE: Shkreli Says Aeterna Zentaris, Cyclacel, Macrocure Worthless",2015-11-30 06:43:00-05:00,CYCC,negative
328023.0,Benzinga's Weekend M&A Chatter,2015-11-29 19:44:00-05:00,CYCC,neutral
328024.0,Hearing Unconfirmed Takeover Chatter Cyclacel Could be Takeover Target for Martin Shkreli and Kalobios,2015-11-27 11:27:00-05:00,CYCC,negative
328025.0,"Cyclacel Pharmaceuticals Reports Q3 EPS $0.08, Sales $735, no estimates",2015-11-12 16:52:00-05:00,CYCC,negative
328026.0,Cyclacel Reports Dosing of First Patient in Phase 1 Trial of CYC065 for Treatment of Advanced Solid Tumors,2015-10-22 07:05:00-04:00,CYCC,positive
328027.0,Benzinga's Top Initiations,2015-10-16 09:27:00-04:00,CYCC,positive
328028.0,H.C. Wainwright Initiates Coverage on Cyclacel Pharmaceuticals at Buy,2015-10-16 07:10:00-04:00,CYCC,neutral
328029.0,"Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas",2015-09-17 07:04:00-04:00,CYCC,negative
328030.0,"Cyclacel Pharmaceuticals Reports Q2 Loss $0.10, no estimates",2015-08-11 16:09:00-04:00,CYCC,negative
328031.0,Cyclacel Pharma Announces Will Sell Up to $8.35M of Shares Through Controlled Equity Offering,2015-07-13 06:07:00-04:00,CYCC,positive
328032.0,Cyclacel Pharmaceuticals Says Entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald to Sell Shares Up to Aggregate Offering Price of $8.35M -8-K,2015-07-13 06:06:00-04:00,CYCC,positive
328033.0,"Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,",2015-07-02 07:04:00-04:00,CYCC,negative
328034.0,"Cyclacel & ManRos Therapeutics Reports Licensing, Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis",2015-06-29 07:00:00-04:00,CYCC,positive
328035.0,"Cyclacel Reports Q1 Loss of $0.19/Share vs Loss of $0.25/Share Est., Sales $512K",2015-05-12 16:09:00-04:00,CYCC,negative
328036.0,"Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Different Anti-Cancer Compounds",2015-04-20 07:01:00-04:00,CYCC,negative
328037.0,Cyclacel Pharmaceuticals Shares Surge After Q4 Results,2015-03-24 17:06:00-04:00,CYCC,positive
328038.0,"Cyclacel Pharmaceuticals Reports Q4 EPS -$0.21 Vs Est -$0.26, Sales $247K, no estimates available",2015-03-24 16:07:00-04:00,CYCC,negative
328039.0,Morning Market Losers,2015-03-04 09:58:00-05:00,CYCC,negative
328040.0,Cyclacel Pharmaceuticals Prices 10M Share Offering at $1.00/Share,2015-03-04 06:04:00-05:00,CYCC,positive
328041.0,Cyclacel Pharma Announces Proposed Common Stock Offering,2015-03-03 17:34:00-05:00,CYCC,neutral
328042.0,"JMP Securities Downgrades Cyclacel Pharmaceuticals to Market Perform, Removes $9.00 PT",2014-12-17 06:56:00-05:00,CYCC,positive
328043.0,Morning Market Losers,2014-12-16 09:57:00-05:00,CYCC,negative
328044.0,"Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis",2014-12-16 07:19:00-05:00,CYCC,positive
328045.0,"Cyclacel Pharmaceuticals, Inc. Reports Q3 EPS of $(0.22) vs $(0.26) Est",2014-11-11 16:05:00-05:00,CYCC,neutral
328046.0,Cyclacel Announces Data Safety Monitoring Board Recommends Continuation of Seamless Phase 3 Trial of Sapacitabine in AML ,2014-10-09 07:02:00-04:00,CYCC,positive
328047.0,"8-K from Cyclacel Shows Presentation Slides: Highlights Sapacitabine in AML, MDS, 'Strong Financial Position, Earlier-Stage Pipeline'",2014-09-26 08:11:00-04:00,CYCC,positive
328048.0,Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL Rearrangements,2014-09-18 07:02:00-04:00,CYCC,negative
328049.0,"Cyclacel Pharmaceuticals, Inc. Reports Q2 EPS of $(0.22) vs $(0.30) Est",2014-08-12 16:12:00-04:00,CYCC,neutral
328050.0,Cyclacel Pharmaceuticals Spikes Higher on Volume,2014-07-11 11:08:00-04:00,CYCC,neutral
328051.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,CYCC,neutral
328052.0,Morning Market Losers ,2014-06-02 09:46:00-04:00,CYCC,negative
328053.0,"Cyclacel Pharmaceuticals, Inc. Reports Q1 EPS of $(0.25) vs $(0.26) Est; Revenue of $396.0K vs $50.0K Est",2014-05-13 16:18:00-04:00,CYCC,neutral
328054.0,"Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering",2014-04-09 16:06:00-04:00,CYCC,neutral
328055.0,Benzinga's Top #PreMarket Losers,2014-04-04 08:22:00-04:00,CYCC,negative
328056.0,Cyclacel Pharmaceuticals Prices 2.9M Share Offering at $3.50/Share,2014-04-04 07:04:00-04:00,CYCC,positive
328057.0,Cyclacel Pharma Reports Offering of Common Shares,2014-04-03 16:22:00-04:00,CYCC,positive
328058.0,"Cyclacel Pharmaceuticals, Inc. Reports Q1 EPS of $(0.19) vs $(0.33) Est; Revenue of $299.0K",2014-03-25 16:07:00-04:00,CYCC,neutral
328059.0,"Earnings Scheduled For March 25, 2014",2014-03-25 05:08:00-04:00,CYCC,neutral
328060.0,Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH ,2013-12-09 07:07:00-05:00,CYCC,positive
328061.0,Cyclacel Pharma Announces Data Safety Monitoring Board Recommends Continuation of SEAMLESS Study of Sapacitabine in AML,2013-11-25 07:18:00-05:00,CYCC,positive
328062.0,"Cyclacel Pharmaceuticals, Inc. Reports Q3 EPS of $(0.32) vs $(0.31) Est",2013-11-12 16:06:00-05:00,CYCC,neutral
328063.0,"Amended 13G Filing from Redmile Group on Cyclacel Pharma Shows Liquidated Position, Had Shown 6.08% Stake as of Jun. 30th",2013-10-03 12:15:00-04:00,CYCC,neutral
328064.0,Morning Market Losers ,2013-09-23 10:14:00-04:00,CYCC,negative
328065.0,Benzinga's Top Pre-Market Gainers,2013-09-20 08:10:00-04:00,CYCC,positive
328066.0,"Cyclacel Pharmaceuticals, Inc. Reports Q2 EPS of $0.10; Revenue of $26.0K vs $200.0K Est",2013-08-14 16:11:00-04:00,CYCC,neutral
328067.0,Cyclacel's Seliciclib to be Evaluated for RA,2013-08-12 16:01:00-04:00,CYCC,neutral
328068.0,"JMP Securities Initiates Coverage on Cyclacel Pharmaceuticals at Market Outperform, Announces $9.00 PT",2013-07-02 08:07:00-04:00,CYCC,positive
328069.0,Cyclacel Pharma Announces Closing of Underwritten Offering,2013-05-21 16:06:00-04:00,CYCC,neutral
328070.0,"Cyclacel Pharma Announces Offering of Common Shares, Amount Not Disclosed",2013-05-15 16:04:00-04:00,CYCC,positive
328071.0,Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock,2013-05-15 16:01:00-04:00,CYCC,neutral
328072.0,"Cyclacel Pharmaceuticals, Inc. Reports Q1 EPS of $(1.18), Down 141% YOY",2013-05-13 16:03:00-04:00,CYCC,neutral
328073.0,Cyclacel Pharma Files $75M Mixed Securities Shelf,2013-04-18 17:30:00-04:00,CYCC,positive
328074.0,Cyclacel Pharma Files $75M Mixed Securities Shelf,2013-04-08 17:13:00-04:00,CYCC,positive
328075.0,"Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene, Dismissal of All Claims in Their Patent Litigation",2013-04-04 07:13:00-04:00,CYCC,negative
328076.0,Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene for $5.5M,2013-04-04 07:13:00-04:00,CYCC,neutral
328077.0,"Cyclacel Pharmaceuticals, Inc. Reports Q4 EPS of $(0.59), Down 20% YOY",2013-03-27 16:07:00-04:00,CYCC,neutral
328078.0,Cyclacel Comments on Key Business Objectives for 2013 ,2013-01-07 07:22:00-05:00,CYCC,neutral
328079.0,Aspire Capital Fund to Purchase Up to $20M of Cyclacel Common Stock for $6.29/Share,2012-12-17 07:29:00-05:00,CYCC,neutral
328080.0,Benzinga's Top Pre-Market Gainers,2012-12-10 08:11:00-05:00,CYCC,positive
328081.0,Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th,2012-12-04 09:12:00-05:00,CYCC,neutral
328082.0,Cyclacel Receives $1.9M Grant,2012-11-05 07:27:00-05:00,CYCC,positive
328083.0,Stocks Hitting 52-Week Highs,2012-10-15 11:06:00-04:00,CYCC,neutral
328084.0,Data Shows Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS ,2012-10-15 07:10:00-04:00,CYCC,neutral
328085.0,Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement ,2012-09-13 07:05:00-04:00,CYCC,neutral
328086.0,Cyclacel Announces Reverse 1-for-7 Stock Split,2012-08-24 09:16:00-04:00,CYCC,neutral
328087.0,Earnings Scheduled For May 14,2012-05-14 02:12:00-04:00,CYCC,neutral
328088.0,Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine  ,2012-04-17 07:04:00-04:00,CYCC,positive
328089.0,Earnings Scheduled For March 29,2012-03-29 03:51:00-04:00,CYCC,neutral
328090.0,Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses on Certain Intellectual Property ,2012-03-22 16:30:00-04:00,CYCC,positive
328091.0,Earnings Scheduled For March 19,2012-03-19 04:53:00-04:00,CYCC,neutral
328092.0,Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes ,2012-02-13 07:00:00-05:00,CYCC,positive
328093.0,"Benzinga's Microcap Movers for Monday February 6, 2012 ",2012-02-06 21:51:00-05:00,CYCC,neutral
328094.0,"Cyclacel Provides Corporate Update at OneMedForum Conference; Re-Analysis ""Insufficient"" ",2012-01-11 12:27:00-05:00,CYCC,neutral
328095.0,Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML  ,2011-12-12 13:02:00-05:00,CYCC,positive
328096.0,Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch,2011-12-07 13:31:00-05:00,CYCC,neutral
328097.0,Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients ,2011-12-07 07:02:00-05:00,CYCC,positive
328098.0,Earnings Scheduled For November 14,2011-11-14 04:24:00-05:00,CYCC,neutral
328099.0,Cyclacel Pharmaceuticals Jumps; Breaks Above Resistance,2011-10-19 14:21:00-04:00,CYCC,neutral
328100.0,Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine  ,2011-10-13 07:05:00-04:00,CYCC,positive
328101.0,Cyclacel Pharmaceuticals Receives Deficiency Notice From Nasdaq Global Select Market,2011-09-22 16:03:00-04:00,CYCC,neutral
328103.0,The Biotech Bump: Cyclacel Pharmaceuticals,2011-07-28 13:57:00-04:00,CYCC,neutral
328104.0,Cyclacel Pharmaceuticals Amends Its Sapacitabine License Agreement With Daiichi-Sankyo,2011-07-18 07:01:00-04:00,CYCC,positive
328105.0,Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock and Warrants,2011-07-07 16:02:00-04:00,CYCC,neutral
328106.0,Cyclacel Pharmaceuticals Announces Pricing of Underwritten Offering at $1.36/Share,2011-07-01 09:15:00-04:00,CYCC,neutral
328107.0,Should Hartford Financial sell Federal Trust Corp. to CenterState Banks Inc.?,2011-05-23 14:36:00-04:00,CYCC,positive
328108.0,"Top Forestry, Wood and Non-Metallic Mining Stocks to watch on 5/23/11- POPE, WY, TREX, DEL, UFPI, HWD, SHZ, MDM, CMP",2011-05-23 04:22:00-04:00,CYCC,positive
328109.0,"Most Popular Stocks Right Now on 5/14/11- RMBS, HCEI, LPHI, DDS, BOCL, FXE, CYCC, EPB, ATEA",2011-05-14 12:32:00-04:00,CYCC,positive
328110.0,"Earnings Scheduled For May 12 (DRYS, JWN, AHII, KSS, DAR, NVDA, CACH, XIN, ACAT, BBOX, ESLR, CXPO, IRWD, CTFO, TREE, CYCC, CXDC)",2011-05-12 02:15:00-04:00,CYCC,neutral
328111.0,"Daytrading Stocks to Watch for 04/28- SSN, HDY, DRYS, ARNA, IRE, CYCC, SOMX, REDF, AIB, YRCW, SHZ, LLNW, LVLT, JSDA",2011-04-28 06:07:00-04:00,CYCC,neutral
328112.0,"CEOWORLD Stocks Picks to Watch on 4/26/11 – NFLX, BIDU, ORCL, YRCW, KOG, SSN, AMZN, PZG, AIG, AMD, GS, POT…",2011-04-26 10:05:00-04:00,CYCC,neutral
328113.0,Cyclacel Pharmaceuticals Files S-3 $75M Mixed Securities Shelf ,2011-04-04 16:56:00-04:00,CYCC,positive
328114.0,Cyclacel Pharmaceuticals Could See Continued Interest As A Result Of Its Radiation Cream (CYCC) ,2011-03-23 15:44:00-04:00,CYCC,positive
328115.0,Cyclacel Pharmaceuticals Up 4% (CYCC) ,2011-03-23 14:39:00-04:00,CYCC,neutral
328116.0,"Earnings Scheduled For March 23 (GIS, OMN, SAI, FUL, RHT, PAYX, SCS, MU, ADK, KH, CYCC)",2011-03-23 01:21:00-04:00,CYCC,neutral
328117.0,Cyclacel Pharmaceuticals Up 9% (CYCC) ,2011-03-15 10:23:00-04:00,CYCC,neutral
328118.0,Cyclacel Completes Previously Announced Private Placement,2010-10-07 16:18:00-04:00,CYCC,neutral
328119.0,Cyclacel Announces Private Placement Financing for Up to $22.1M,2010-10-05 09:19:00-04:00,CYCC,neutral
328120.0,CYCC - Cyclacel Pharmaceuticals - Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS:,2010-07-01 08:55:00-04:00,CYCC,positive
328121.0,CYCC - Cyclacel Pharmaceuticals - Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS:,2010-07-01 08:41:00-04:00,CYCC,positive
328122.0,"Benzinga’s Top Pre-Market Gainers (OMNI, DYAX, CYCC, WPRT, FCEL)",2010-06-04 08:54:00-04:00,CYCC,positive
328123.0,"Benzinga’s Top Pre-Market Gainers (CSTR, DE, DVN, CYCC, NLST)",2010-02-17 08:20:00-05:00,CYCC,positive
328124.0,"Benzinga’s Top Pre-Market Gainers (SNA, BKC, HDNG, AFFX, CYCC, KLIC, ENTG)",2010-02-04 08:32:00-05:00,CYCC,positive
328125.0,"Benzinga’s Top Pre-Market Losers (SEED, MPGI, CYCC, NFLX, ROSG, PEIX)",2010-01-14 08:47:00-05:00,CYCC,negative
328126.0,"Benzinga’s Top Pre- Market Gainers (ATSI, BCRX, BIDU, CYCC, ERC, MRNA, CLNE)",2010-01-13 08:25:00-05:00,CYCC,positive
328127.0,"This Week's Most-Purchased Stocks to Date - AA, CYCC, F, C",2010-01-12 23:48:00-05:00,CYCC,neutral
328128.0,CYCC Shares Continue To Stand Out In Pre-Market Trading,2010-01-08 09:29:00-05:00,CYCC,positive
328129.0,"Benzinga’s Top Pre- Market Gainers (INTC, DB, CYCC, BCS, QCOM, CAF, GME)",2010-01-08 08:10:00-05:00,CYCC,positive
328130.0,"Benzinga’s Biggest Losers (HLCS, CYCC, SNSS, AMED, APKT) ",2009-12-16 12:01:00-05:00,CYCC,negative
328131.0,NASDAQ Warns It Could Delist Cyclacel,2009-12-15 17:47:00-05:00,CYCC,negative
